Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Expenses: 2016-2025

Historic Operating Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $52.2 million.

  • Rocket Pharmaceuticals' Operating Expenses fell 24.74% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.5 million, marking a year-over-year decrease of 8.51%. This contributed to the annual value of $273.2 million for FY2024, which is 5.22% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Operating Expenses is $52.2 million, which was down 26.57% from $71.1 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Operating Expenses high stood at $73.7 million for Q2 2024, and its period low was $34.0 million during Q2 2021.
  • In the last 3 years, Rocket Pharmaceuticals' Operating Expenses had a median value of $65.4 million in 2023 and averaged $65.5 million.
  • The largest annual percentage gain for Rocket Pharmaceuticals' Operating Expenses in the last 5 years was 81.28% (2021), contrasted with its biggest fall of 25.16% (2021).
  • Over the past 5 years, Rocket Pharmaceuticals' Operating Expenses (Quarterly) stood at $44.3 million in 2021, then spiked by 55.83% to $69.1 million in 2022, then decreased by 8.40% to $63.3 million in 2023, then dropped by 0.92% to $62.7 million in 2024, then declined by 24.74% to $52.2 million in 2025.
  • Its Operating Expenses stands at $52.2 million for Q3 2025, versus $71.1 million for Q2 2025 and $64.4 million for Q1 2025.